ViroCure Australia

ViroCure is a clinical-stage biotechnology company specializing in the development of next-generation oncolytic virus therapies for the treatment of solid tumors. Headquartered in South Korea with a strategic presence in Australia, the company leverages its proprietary platform to engineer viruses that selectively infect and lyse cancer cells while stimulating a robust systemic immune response. Its lead candidate, RC402, is a naturally occurring reovirus currently being evaluated in Phase 1 clinical trials in Australia for advanced malignancies, including gastric and colorectal cancers. ViroCure's pipeline also includes several preclinical candidates designed to enhance therapeutic efficacy through viral engineering and combination strategies. The company's Australian operations are central to its global clinical development strategy, benefiting from the region's streamlined regulatory environment for early-phase trials.